巨噬细胞移动抑制因子和基质金属蛋白酶9与2型糖尿病合并冠心病的关系研究

目的探讨血清巨噬细胞移动抑制因子（MIF）、基质金属蛋白酶9（MMP-9）与2型糖尿病患者合并冠心病的关系。方法132例2型糖尿病患者分为合并冠心病组（92例，行冠状动脉造影），根据冠状动脉病变范围再分为单、双、三支病变组，分别为16、34、42例。2型糖尿病无冠心病组（40例），前者选取40例健康体验者作为正常对照组。血浆MIF、MMP-9浓度通过酶联免疫吸附（ELISA）法测定。结果2型糖尿病合并冠心病组MIF、MMP-9水平高于2型糖尿病无冠心病组[（22±7）μg/L比（18±6）μg/L，（20±6）μg/L比（16±8）μg/L]，且2组MIF、MMP-9水平均高于正常对照组[（5±3）、（6±4）μg/L]，差异均有统计学意义（均P〈0．05）；随冠状动脉病变范围的增加，MIF、MMP-9浓度逐渐升高，并且随Gensini积分的增高而增高。结论MIF、MMP-9增高与2型糖尿病合并冠心病发生、发展明显相关。

Relationship between serum macrophage migration inhibitory factor, matrix metallo proteinate-9 level in type 2 diabetic patients with coronary heart disease

Objective To study the relation between serum macrophage migration inhibitory factor （MIF） and matrix metallo proteinate-9 （MMP-9） level in type 2 diabetic patients （T~DM） with coronary heart disease （CHD）. Methods Totally 92 patients with T2DM with CHD who underwent coronary angiography were divided into one-vessel, two- vessel, three- vessel group, meanwhile T2DM without CHD group （40 patients） and the control group （40 patients）. The plasma MIF, MMP-9 concentration were measured by ELISA. Results MIF and MMP-9 concentration was significantly higher in T2DM with CHD group [ （22 ± 7 ） μg/L vs （20 ± 6） μg/L] than those in T2 DM without CHD group [ （ 18±6） vs （ 16± 8 ） μg/L l- MIF and MMP-9 concentrations were increased gradually with the increase of extent of coronary lesion and the Gensini score. Conclusions The high levels of serum MIF, MMP-9 play an important role in the development of CHD in T2 DM.